Development of Microparticulate Sustained Release Dosage Form of Emtricitabine: An Anti-HIV Drug

A. FATHIMA, B.N. VEDHA HARI and D. RAMYA DEVI*

School of Chemical and Biotechnology, SASTRA University, Thanjavur-613 401 India

*Corresponding author: Fax: +91 4362 264120; Tel: +91 4362 264101/108; E-mail: ramya@scbt.sastra.edu

Received: 11 May 2013;

Accepted: 14 August 2013;

Published online: 28 April 2014;

AJC-15078

Emtricitabine is a nucleotide reverse transcriptase inhibitor used for HIV infections, with oral bioavailability of 93 %. Microparticles loaded with emtricitabine were formulated through ionotropic gelation method using sodium alginate as retardant polymer and calcium chloride as cross linker. The concentration of hydroxy propyl methyl cellulose and sodium alginate were varied as 50-300 mg and 100-900 mg respectively using 3^2 factorial design. The prepared microparticles were evaluated for particle size distribution (322.66 to 553.40 μ m), percentage yield (96.68-98.33 %) drug content (92.85-95.23%) and drug entrapment efficiency (27.41 to 52.44 %). The FT-IR spectroscopic analysis indicated the minimum drug polymer interaction during preparation. The stability and uniform dispersion of drug in the polymeric matrix was confirmed by DSC and XRD studies. The *in vitro* release profile indicated that increase in intensity of cross linking decreased the rate of drug release, with showed significant sustained release effect of the dosage form for more than 8 h.

Keywords: Emtricitabine, Microparticles, Sodium alginate, Response surface methodology.

INTRODUCTION

Microparticles are solid rigid particles within the size ranging from 1 to 1000 μ m. Depending upon the preparation of microparticles, the drug can be dissolved, entrapped, encapsulated using specific polymers¹. Microparticles can be of matrix or reservoir type where drug is uniformly distributed in the system and provide a sustained release of the drug²⁻³. Microparticles have the significance of providing prolonged action by circulating within system for expanded time schedule in addition to targeting particular organ, especially to deliver macromolecules like proteins, peptides and genes⁴⁻⁶.

The advantages of the microparticles are easy administration to deliver macromolecules by a variety of routes and effectively control the release of drugs over the periods ranging from few hours to months, because of effective protection of encapsulated drug against degradation⁷.

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and is an analogue of cytidine which is used in the treatment of HIV infections. The working principle of the drug is inhibition of reverse transcriptase and also lowering the quantity of viral load which can help to increase the activity of immune system. Emtricitabine is having a bioavailability of 93 % and soluble in water, methanol and practically insoluble in dichloromethane. Emtricitabine is used in the combination with many other anti-viral drugs to treat HIV infections, commonly named as (HAART)⁸⁻¹⁰.

Alginate is naturally occurring polymeric substance obtained from brown algae, mainly consisting of blocks of mannuronic acid (M), guluronic acid (G) and mannuronic - guluronic acid (MG)¹¹, specially used for sustained delivery of drugs. Sodium alginate microparticles are prepared by ionic gelation technique which involves the addition of droplets of this polymer through small orifice into CaCl_2 solution, where the calcium ions cross links the viscous gel polymer into rigid micro beads. This approach has certain black marks, to be precise, the tear drop shape of the microparticles produced, the limitation in reducing microparticle diameter and the complexity in manufacturing leveling up^{12,13}. This proposed method can allow modifications in the size and dimension of the microparticles according to the orifice used *i.e.*, the size of the needle^{14,15}.

The intention of the present investigation is to formulate and check the quality parameters for the novel drug delivery intended for extended action *via* per oral route, namely microparticles of emtricitabine with sodium alginate by ionic - gelation method and also optimizing the formulation with statistical tool (RSM) to provide high entrapment efficiency, reducing dosing frequency and sustained release of the drug.

EXPERIMENTAL

Emtricitabine was presented by Matrix, Hyderabad, India. Hydroxyl propyl methyl cellulose (SD Fine Chem. Limited,

Mumbai, India), sodium alginate (Chemspure, Chennai, India) were obtained from commercial sources. All the chemicals involved in this work were of laboratory analytical grade.

Formulation of emtricitabine microparticles: The block polymeric substance sodium alginate along with the muco-adhesive polymer mixture was dissolved in water to obtain a jelly solution into which the drug was dissolved or dispersed, which was then cross linked using calcium chloride by ionic gelation method^{16,17}, to retard the release of the drug encapsulated or dispersed within its matrix. Trial formulations were prepared by this technique by varying the ratios of sodium alginate, being dissolved in required quantity of purified water. Next was the slow addition of mucoadhesive polymer into the alginate solution by way of nonstop mixing followed by sonication for 20 min to obtain a homogenous mixture. The drug substance Emtricitabine was added to the block polymer-mucoadhesive polymer combined mixture and stirred systematically until a clear solution was obtained. This complex solution was dropped using an insulin syringe into the 5 % calcium chloride for cross linking the matrix. The cross linked particles were retained in the magnetic stirrer for 1 h with continuous stirring to ensure the curing process to be completed and also recover homogenous sized and shaped stiff microparticles. The microparticles were screened through filter or decant, rinsed constantly using deionized water and then kept for drying at 45 °C for 12 h. Nine trials planned by the factorial design by changing the ratio of block polymer and muco-adhesive polymer was scheduled in Table-1.

TABLE-1
FACTORIAL DESIGN FOR EMTRICITABINE
MICROPARTICLE FORMULATION

Formulation code	Hydroxy propyl methyl cellulose (HPMC)	Sodium alginate
EMF1	-1	0
EMF2	0	0
EMF3	1	1
EMF4	-1	1
EMF5	-1	-1
EMF6	1	-1
EMF7	0	1
EMF8	0	-1
EMF9	1	0

- HPMC (mg): -1=50; 1=300; 0=175
- Sodium alginate (mg): -1=100; 1=900; 0=500
- Drug (mg): 100

Estimation of drug content: An accurately weighed 10 mg or equivalent of drug portion of microparticles was taken in a 100 mL standard measurement flask and added with 5 mL of methanol to dissolve the drug and finally added phosphate buffer pH 7.4 to ensure the standard volume^{17,18}. After filtration and making apposite dilution, the solution was examined with UV-visible spectrophotometer (Perkin Elmer, USA) to estimate the amount of drug encapsulated in the microparticles.

Determination of percentage yield: The total amount of microparticles was weighed and the percentage yield was calculated depending upon the drug and the polymer quantity used in the formulation.

$$\% \text{ Yield} = (\text{Practical yield} / \text{Theoretical yield}) \times 100$$

Calculation of drug entrapment level: A specific amount of microparticles containing drug were trampled to form powder and dissolved in 10 mL of phosphate buffer pH 7.4 followed by sonication being done for 0.5 h. The solution so obtained was then passed through Whatmann filter paper and the resultant filtrate was analyzed spectrophotometrically using UV-visible spectrophotometer (Perkin Elmer, USA) at 278 nm. The percentage of drug entrapped within the microparticles shall be estimated using the formula,

$$\text{Drug entrapment efficiency} = (\text{Experimental drug content} / \text{Theoretical drug content}) \times 100$$

Detection of particle Size: The size of microparticles was measured through optical microscopy technique, with the help of compound light microscope (Khera instruments, Pvt Ltd, New Delhi) which was previously calibrated by eye piece micrometer. Small amount of microparticles were placed on clean dried glass slide (5 cm × 1 cm) having thin film of oil layer (glycerin), placed on the platform and focused with 10X. Approximately 100 particles were measured for its diameter and the results were tabulated and mean was calculated¹⁷.

FT-IR spectroscopy analysis: A small quantity of the emtricitabine microparticles was ground along with IR grade dried potassium bromide which specifically avoids the unwanted light transmission and scattering problems. The mechanical die press is used to convert the powdered mixture into a thin disc through which the IR beam can be passed to determine the interaction of drug and excipients¹⁸⁻²⁰.

In vitro drug release studies: An accurately weighed 10 mg or its equivalent amount of emtricitabine microparticles was positioned in 200 mL of dissolution medium (phosphate buffer pH 7.4), monitored at warmth condition of 37 ± 0.5 °C and stimulated at a rapidity of 75 rpm using USP dissolution apparatus type I (basket). At different intervals of sampling moment, specified amount of liquid was sampled out from the dissolution jar and an identical volume of warm medium was replaced again to establish the sink situation. The liquids so obtained were screened and exposed at 230.4 nm in UV-visible spectrophotometer (Perkin Elmer, USA) against the phosphate buffer pH 7.4 used as blank.

Differential scanning calorimetric (DSC) analysis: The physicochemical compatibilities of the optimized formulations were analyzed by differential scanning calorimetry. The DSC thermograms of the crushed microparticles and the pure drug were obtained from a differential scanning calorimeter (Perkin Elmer, USA) with a thermal analysis data station system, computer and plotter interface. The device was previously calibrated using indium as standard. The samples (2 mg) were analyzed at 30-220 °C¹⁸⁻²⁰.

X-Ray diffraction (XRD) analysis: Emtricitabine microparticles and the pure drug were experimented using Rigaku ultima III XRD analyzer with copper target, to identify their crystallinity nature. The set up of the instrument was 40 Kv voltage with 30 mA current at room temperature and the samples being weighed down on the diffractometer and scanned at range of 2θ values from 3° to 60° at a scan rate of 0.05 °C/min²¹⁻²³.

Experimental analysis and statistical design: A 3² factorial design was employed to design sustained release microparticles for Emtricitabine²⁴⁻²⁶. This design was suitable

TABLE-2
ACTUAL VALUES AND CODED VALUES OF EMTRICITABINE
- SODIUM ALGinate MICROPARTICLES

Factors	Actual values			Coded values		
	Low level	Medium level	High level	Low level	Medium level	High level
HPMC	50	175	300	-1	0	1
Sodium alginate	100	500	900	-1	0	1

for response surface of quadratic equations in which the two independent variables were hydroxy propyl methyl cellulose (X_1) and sodium alginate (X_2). The actual and coded levels of the design were represented in Table-2. The lower, intermediate and higher levels of each factor coded as 0, +1 and -1 respectively. The dependent variables selected were drug entrapment efficiency (Y_1) and % drug release (Y_2)²⁷⁻²⁹.

RESULTS AND DISCUSSION

The practical yield obtained for the various trials were calculated with respect to its theoretical yield (Table-3), which

ranged between 96.68 to 98.33 %. Percentage yield greater than 90 % suggests that this technique shall be effectively adapted for the formulation of emtricitabine microparticles¹⁷.

Drug content: A wide variation in drug loading effect was observed for the experimented formulations with respect to changes in polymer : emtricitabine ratio. The percentage drug content of all the formulations was in the range of 92.85-95.23 % (Table-3). The total content of the formulation remained within the required limits, which signify the presence of unmodified drug in the developed formulation¹⁸.

Drug entrapment efficiency: The percentages of encapsulation of all the formulation were in the range of 27.41 to 52.44 % (Table-3). The change in encapsulation efficiency observed between all the formulations was due to the difference in the proportion of polymer used. With reference to the results, it was clear that by rising the quantity of polymer with respect to the drug, the entrapment level can be elevated.

Particle size: The dimensions of the microparticles of emtricitabine were analyzed by optical microscopy (Fig. 1). All the formulation of Emtricitabine microparticles showed regular size divisions. The particle size was found to be within the range of 322.66 to 553.40 μm (Table-3). Even though the

Fig. 1. Optical microscopic images of Emtricitabine-sodium alginate microparticles

TABLE-3
COMPARATIVE EVALUATION OF PHYSICAL PARAMETERS OF EMTRICITABINE MICROPARTICLES

S. No.	Formula code	Drug : polymers ratio	Particle size (μm)	(%) yield	Drug content (%)	Drug entrapment efficiency (%)	(%) Drug release at 8 th h
1	EMF1	1:0.5:5	553.40 $\pm$ 23.1	98.33	95.23 $\pm$ 0.59	52.44 $\pm$ 0.63	79.77 $\pm$ 0.88
2	EMF2	1:1.75:5	330.34 $\pm$ 16.2	97.16	93.16 $\pm$ 0.89	42.50 $\pm$ 0.75	73.45 $\pm$ 0.69
3	EMF3	1:3:9	400.95 $\pm$ 56.9	98.07	94.07 $\pm$ 0.75	27.41 $\pm$ 0.64	67.66 $\pm$ 0.55
4	EMF4	1:0.5:9	322.66 $\pm$ 8.08	97.23	93.23 $\pm$ 0.66	35.66 $\pm$ 0.62	79.27 $\pm$ 0.77
5	EMF5	1:0.5:1	-	-	-	-	-
6	EMF6	1:3:1	-	-	-	-	-
7	EMF7	1:1.75:9	353.22 $\pm$ 33.4	96.68	92.85 $\pm$ 0.54	31.68 $\pm$ 0.86	70.56 $\pm$ 0.99
8	EMF8	1:1.75:1	-	-	-	-	-
9	EMF9	1:3:5	340.65 $\pm$ 30.9	97.07	93.07 $\pm$ 0.98	42.56 $\pm$ 0.91	68.36 $\pm$ 0.58

polymer: drug ratio was varied in each trial, the size distribution did not show significant difference between them²¹.

The formulation EMF5, EMF6 and EMF8 designed by the factorial method, did not produce microparticles by the ionic gelation method, since the ratio of sodium alginate to drug and polymer was not feasible to give required viscosity to the solution to be injected through the insulin needle. So, the microparticles were not formed with required size and rigidity.

in vitro Drug release and its kinetics: Microparticles of all the formulation had slow drug release about 25 % within 1 h. Then the formulations could deliver the drug for a study period of 8 h, the percentage being varied between 68.36-79.77 % at 8 h (Table-3) based on the polymer: drug ratio in each individual. Even though the percentage of drug release did not show much variation, the formulation EMF1 showed elevated level of drug liberated at the stop time of 8 h compared to other formulations (Fig. 2). This may be due to superior loading effect, enhanced encapsulation potency and amplified particle size. The mechanism by which drug released from the formulations were verified by fitting the data obtained for *in-vitro* release studies to various kinetics equations. The r^2 value (Table-4) of the optimized formulation EMF1 indicated Higuchi model of release mechanism, which proved a time dependent profile based on diffusion and erosion of the system³⁰.

Fig. 2. Comparative *in vitro* drug release profile of emtricitabine-sodium alginate microparticles

TABLE-4 DRUG RELEASE KINETICS FROM EMTRICITABINE - SODIUM ALGINATE MICROPARTICLES						
Ratio	EMF1	EMF2	EMF3	EMF4	EMF7	EMF9
	r^2					
Zero order	0.9295	0.9699	0.9974	0.9778	0.9757	0.9771
First order	0.8513	0.8513	0.8513	0.8513	0.8513	0.8513
Higuchi	0.9923	0.9802	0.9942	0.9878	0.9933	0.9936
Korsmeyer	0.9765	0.9947	0.9672	0.9362	0.9569	0.9918
Hixon	0.9861	0.985	0.9947	0.9623	0.9843	0.9952

FT-IR spectra analysis: FTIR spectra of pure drug revealed³¹ its principle peaks of C-N stretch at 1154.4 cm^{-1} , C=O stretch at 1629.28 cm^{-1} and O-H stretch at 3421.27 cm^{-1} as shown in Fig. 3. The IR bands of microparticles formulation presented the peaks for both drug and the polymer, in which the corresponding peaks of the drug was found to be less intense, indicating mild interaction between the drug and polymer. The deviation in the wave number and the peak width

was observed between the pure drug and the microparticle formulation, which may be due to encapsulation of drug within the polymer by cross linking and hydrogen bonding interactions.

Fig. 3. FTIR spectrum for (a) emtricitabine (pure drug), (b) microparticle formulation (EMF1)

Differential scanning calorimetric analysis: DSC thermogram (Fig. 4) of pure emtricitabine showed a sharp endothermic peak at 153.40°C and an exothermic peak at 256.81°C indicating its melting point and the decomposition level, respectively^{31,32}. The microparticle formulation have shown a shift in the peaks of the drug at 193.25°C and 293.13°C , compared to the pure sample, which was due to the mild interaction of the drug with the polymers during cross linking process. In addition, the peaks of the polymers were observed at $> 56^\circ\text{C}$ and $> 300^\circ\text{C}$ for HPMC (68°C) and sodium alginate (363°C and 409°C) respectively³³, which also was slightly deviated from its normal ranges proving their minimum interaction with the drug.

Fig. 4. DSC study for (a) emtricitabine (pure drug) (b) microparticulate formulation (EMF1)

X-ray diffraction study (XRD) analysis: The X-ray diffractogram of pure emtricitabine and its microparticle formulation (EMF1) were showed in Fig. 5. The spectrum of pure emtricitabine confirmed frequent distinct peaks to prove the crystallinity of the drug. No characteristic XRD pattern was observed in the case of drug loaded microparticles, which depicted close intense peaks, due to the semicrystalline or amorphous state modification of the drug and the polymer used. This clearly indicated changes in the crystalline state of the drug occurred during the preparation of the microparticles by the ionotropic gelation method.

Experimental analysis and statistical design: ANOVA was used to carry out the analysis of data and record the responses. The F-test was used to evaluate the individual parameter and a polynomial equation used for multiple linear regression analysis (MLRA). The experimental runs with independent variables and corresponding responses for the 9 formulations are presented in Table-3. The data was fitted with various models of statistical tools like linear, 2FI (two factor interaction), quadratic and cubic for the selected two responses using design expert soft ware (Design 8 Expert TM), it helps to choose the good fit model for better analysis and finally the good fit of the model was evaluated using ANOVA²³.

R^2 (multiple correlation coefficient), adjusted R^2 (adjusted multiple correlation coefficient) and PREES (predicted residual sum of square) provided by design-expert software were used

Fig. 5. XRD study for (a) emtricitabine (pure drug), (b) microparticulate formulation (EMF1)

as factors for selection of adequate models. With the above data quadratic model was choosen as a good fit model due to its small predicted residual sum of squares (PRESS) and it gives the quantity of robust model to the points in experiments. For the better data point fit the PRESS must be small.

$$Y = \beta_0 + \beta_1 A + \beta_2 B + \beta_3 AB + \beta_4 A^2 + \beta_5 B^2 \quad (1)$$

where β_0 is an intercept and β_1 - β_5 are coefficient of respective factors and their interaction response are following,

Response 1: Drug entrapment efficiency (Y1): Value of "Prob > F" was less than 0.0500 which indicate that the model terms were significant. In this case A, B and AB were shown as significant model terms.

$$\begin{aligned} \text{Drug EE (Y1)} = & +97.13 + 0.53 A + 0.47 B - 0.068 AB \\ & + 0.63 A^2 - 0.69 B^2 \end{aligned} \quad (2)$$

Response 1: Drug release (Y2): Value of "Prob > F" was less than 0.0500 which indicate that the model terms were significant. In this case A and B were shown as significant model terms.

$$\begin{aligned} \text{Drug release (Y2)} = & +72.35 - 3.78 A + 1.28 B - 2.81 AB \\ & - 3.78 A^2 + 1.28 B^2 \end{aligned} \quad (3)$$

Mathematical relationship in the form of quadric equations for all responses and their standardized main effects are shown in Tables 5 and 6. Positive and negative sign before a coefficient in quadratic models indicate a synergistic effect or an antagonist effect for the factor. The coefficient of A, B and AB

were significant ($P < 0.05$). Increasing the concentration of sodium alginate (B) resulted in reduction of drug release. And its interaction terms had a retardation influence on the release of emtricitabine^{25,26}.

3D response surface and contour plot showing the effect of hydroxy propyl methyl cellulose and sodium alginate on drug entrapment efficiency and percentage drug release showed in Figs. 6 and 7. Drug release was found to be in sustained manner and in a regular fashion as concentration of

Figs. 6. (a) 3D Response surface plot and (b) Contour plot showing the effect of the hydroxy propyl methyl cellulose and sodium alginate on drug entrapment efficiency

Fig. 7. (a) 3D Response surface plot and (b) Contour plot showing the effect of the hydroxy propyl methyl cellulose and sodium alginate on percentage drug release

polymer was increased. The optimized formulation was evaluated for drug entrapment efficiency and percentage drug release, Table-7 enlisted the value of the observed and predicted response for the optimized formulation of emtricitabine. The data clearly indicate that the dependent variables were strongly influenced by the independent variables²⁸.

TABLE-5
ANOVA FOR EMTRICITABINE MICROPARTICLES DRUG ENTRAPMENT EFFICIENCY

Source	SS	DF	MS	F	P	Model significant/ non-significant relative noise
Model	4.78	5	0.96	50.86	< 0.0001	Significant
Drug EE	1.72	1	1.72	91.27	< 0.0001	Significant
% drug release	1.30	1	1.30	68.95	< 0.0001	Significant
Residual	0.13	7	0.019			
Core total	4.92	12				

Drug EE - (Drug entrapment efficiency); DF - degree of freedom, SS - sum of square, MS - mean sum of square, F - Fischer's ratio

TABLE-6
ANOVA FOR EMTRICITABINE MICROPARTICLES DRUG RELEASE

Source	SS	DF	MS	F	P	Model significant/ non-significant relative noise
Model	127.38	3	42.46	13.47	0.0011	Significant
Drug EE	85.88	1	85.88	27.25	0.0005	Significant
% drug release	9.86	1	9.86	3.13	0.1108	Significant
Residual	28.37	9	3.15			
Core total	155.75	12				

Drug EE - (Drug entrapment efficiency); DF indicates degree of freedom; SS, sum of square; MS, mean sum of square; and F, Fischer's ratio

TABLE-7
PREDICTED AND OBSERVED RESPONSE OF THE OPTIMIZED
FORMULATION FOR EMTRICITABINE MICROPARTICLES

Response	Predicted	Observed	Residuals
Drug EE	98.298	98.330	0.032
% Drug release	80.227	79.420	-0.807
Drug EE - (Drug entrapment efficiency); Residual = observed value – predicted value			

Conclusion

Sustained release microparticles of water soluble drug emtricitabine using anionic polymer can be successfully prepared by ionic gelation method with better yield of production, higher content of drug and improved potency of encapsulation. All the microparticles demonstrate definite morphology (smooth surface) and unique dimensional characteristics (spherical shape) with fine size range divisions. From FTIR, DSC and XRD, it could be revealed that Emtricitabine microparticle formulation demonstrated less significant interaction within the polymers used. The *in vitro* release studies proved the typical sustained release of drug for more than 8 h. The application of 3² factorial design was very useful for optimization of emtricitabine microparticles. The data so obtained clearly indicate that the particle size, drug content, encapsulation property variables were strongly influenced by the changes in ratio of the drug and polymers variables. This dosage form ensures sustained release of the water soluble drug which can extend the interval of action, circumvent early dose clearance.

ACKNOWLEDGEMENTS

The authors are grateful to the Management of SASTRA University for providing the necessary infrastructure and support to complete this work successfully.

REFERENCES

1. N.P. Abhay, R.S. Sadhana and W.T. Mahesh, *Int. J. Pharm. Res. Dev.*, **3**, 99 (2011).
2. M.N.V. Satheesh and K. Shivani, *Int. J. PharmTech. Res.*, **3**, 1242 (2012).
3. D.L. Wise, *Handbook of Pharmaceutical Controlled Release Technology*, CRC Press, New York, p. 271 (2000).
4. R. Langer and J. Folkman, *Nature*, **263**, 797 (1976).
5. S.D. Putney and P.A. Burke, *Nat. Biotechnol.*, **16**, 153 (1998).
6. J. Moore, *The Drug Delivery Outlook to 2005*, Business Insights Ltd., (1999).
7. J. Siepmann, *Prog. Colloid Polym. Sci.*, **15**, 133 (2006).
8. <http://www.drugs.com/sfx/atrilpla-side-effects.html>.
9. P. Emillio, *Archive of SID*, **8**, 125 (2008).
10. J.E. Gallant, E. DeJesus, J.R. Arribas, A.L. Pozniak, B. Gazzard, R.E. Campo, B. Lu, D. McColl, S. Chuck, J. Enejosa, J.J. Toole and A.K. Cheng, *N. Engl. J. Med.*, **354**, 251 (2006).
11. K.D. Malay and C.S. Prakash, *Acta Polon. Pharm. Drug Res.*, **64**, 253 (2007).
12. C.M. Silva, A.J. Ribeiro, M. Figueiredo, D. Ferreira and F. Veiga, *AAPS J.*, **7**, 903 (2005).
13. R.W.J. Lencki, R.J. Neufeld and T. Spinney, US Patent 4822534 (1989).
14. K. Nilsson, S. Bimbaum, S. Flygare, L. Linse, U. Schroder, U. Jeppsson, P.O. Larsson, K. Mosbach and P. Brodelius, *Eur. J. Appl. Microbial. Biotechnol.*, **17**, 319 (1983).
15. L.S.C. Wan, P.W.S. Heng and L.W. Chan, *J. Microencapsul.*, **9**, 309 (1992).
16. V. Belgamwar, V. Shah and S. Surana, *Curr. Drug Deliv.*, **6**, 113 (2009).
17. P. Venkatesan, R. Manavalan and K. Valliappan, *J. Pharm. Sci. Res.*, **1**, 26 (2009).
18. B.N. Vedha Hari, A. Brahma Reddy and B. Samyuktha Rani, *J. Young Pharmacists*, **2**, 350 (2010).
19. J. Luypaert, M.H. Zhang and D.L. Massart, *Anal. Chim. Acta*, **478**, 303 (2003).
20. S. Roy, S.G. Panpalia, B.C. Nandy, V.K. Rai, L.K. Tyagi, S. Dey and K.C. Meena, *Int. J. Pharm. Sci. Drug Res.*, **1**, 36 (2009).
21. B.C. Gangadhar, R.S. Sunder, M.V. Vimal Kumar, M.S. Raju and M.S. Kiran, *Int. J. Drug Discovery*, **2**, 8 (2010).
22. L. Pachuaui and B. Mazumder, *Int. J. PharmTech Res.*, **1**, 966 (2009).
23. L. Pachuaui, S. Sarkar and B. Mazumder, *Trop. J. Pharm. Res.*, **7**, 995 (2008).
24. H. Eroglu, R. Alpar and L. Toner, *J. Pharm. Sci.*, **33**, 144 (2008).
25. P.D. Chudiwal, P.L. Pawar, M.A. Nagaras and S.K. Mandlik, S.V. Pandya and P. Wakte, *Int. J. PharmTech Res.*, **1**, 1366 (2009).
26. J. Shaji and A. Shinde, *Int. Res. J. Pharm.*, **3**, 166 (2012).
27. G. Deshmukh, D. Ruikar, A.K. Seth, T. Ghelani, H. Patel, J. Patel and J. Patel, *Pharm. Sci. Monitor: Int. J. Pharm. Sci.*, **2**, 26 (2011).
28. S.C. Jagdale, S.A. Ghorpade, B.S. Kuchekar and A.R. Chabukswar, *Int. J. Pharm. Applications*, **3**, 181 (2011).
29. A.V. Pande, U.A. Nimbalkar, M.V. Dhoka and P.A. Sonawane, *Int. J. Res. Pharm. Chem.*, **1**, 448 (2011).
30. G. Singhvi and M. Singh, *Int. J. Pharm. Studies Res.*, **2**, 77 (2011).
31. <http://www.drugbank.ca/drugs/DB00879>.
32. I.A. Kartsonakis and G. Kordas, *J. Am. Ceram. Soc.*, **93**, 65 (2010).
33. T. Phaechamud, A. Mesnukul and K. Yodkhum, *Indian J. Pharm. Sci.*, **71**, 413 (2009).